Response to Treatment With Oral Alitretinoin in Patients With Chronic Hand Eczema That Is Refractory to Treatment With Potent Topical Corticosteroids: Experience in 15 Patients
| Autor: | Ingrid Aguayo-Leiva, Pedro Jaén-Olasolo, S. Urrutia |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Vitamin
Agonist medicine.medical_specialty Histology business.industry medicine.drug_class Retinoic acid Dermatology medicine.disease Pathology and Forensic Medicine Surgery Alitretinoin chemistry.chemical_compound chemistry Thyroid-stimulating hormone Refractory medicine Elevated transaminases Retinoid business medicine.drug |
| Zdroj: | Actas Dermo-Sifiliográficas (English Edition). 102:616-622 |
| ISSN: | 1578-2190 |
| DOI: | 10.1016/j.adengl.2010.10.008 |
| Popis: | Background Alitretinoin (9- cis -retinoic acid) is an endogenous derivative of vitamin A and functions as an agonist of both families of nuclear receptors (retinoic acid receptor-α, -β, -γ; retinoid X receptor-α, -β, -γ). It has been investigated in the treatment of chronic hand eczema in many studies in recent years and the results have been promising. Objectives To evaluate the efficacy and safety of oral alitretinoin in the treatment of chronic hand eczema that is refractory to treatment with potent topical corticosteroids and to analyze the long-term response to treatment. Materials and methods A prospective, observational, descriptive study was undertaken in 15 patients with chronic hand eczema that was refractory to treatment with potent topical corticosteroids. Patients were administered oral alitretinoin 30 mg/d for 3 months followed by 6 months of follow-up. Results A complete response, with “clear” hands was obtained in 7 patients (47%), 5 patients (33%) achieved a partial response (almost clear hands), 1 patient (7%) showed substantial improvement, 1 (7%) showed moderate improvement, and 1 patient (7%) did not respond to treatment. Relapse occurred within 6 months of treatment suspension in 54% of cases. The treatment was well tolerated. Side effects, observed in 50% of cases, were mild (headache, elevated lipid levels, slightly elevated transaminase levels, and epigastric pain), except in 1 patient, who had a substantial reduction in thyroid stimulating hormone levels. Conclusions The results of our study support the proposal of alitretinoin as an effective and safe short-term and medium-term treatment for chronic hand eczema in patients whose disease is refractory to treatment with potent topical corticosteroids. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect